S
StemoniX
Biotech & Life Sciences · Maple Grove, United States · Founded 2014
StemoniX is revolutionizing the production, growth, and development of stem cell and stem cell technologies MoreLess
StemoniX specializes in creating human organoid models and advanced analytical algorithms to accelerate drug discovery and reduce development costs. The company partners with leading biopharma, academic, and government institutions to provide functional models, expert services, and actionable results. StemoniX's core offerings include off-the-shelf and custom disease models, as well as their Assay AnalytiX platform, which combines human biology and artificial intelligence to deliver deeper insights and faster returns from experiments. The company serves clients in the pharmaceutical and biotechnology sectors, focusing on improving the efficiency and effectiveness of drug development processes. StemoniX generates revenue through the sale of its organoid models, analytical services, and custom research solutions.
Keywords: human organoid models, drug discovery, AI analytics, biopharma partnerships, disease models, Assay AnalytiX, iPSC, cardiomyocytes, neurons, toxicology studies.
Company overview
StemoniX company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2014
- Headquarters
- Maple Grove, United States
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 88.9
- Investment activity
- 1 companies · latest Mar 2021
- Capital deployed
- —
- Preferred round
- MERGER
Valuation & funding
StemoniX funding history
Company financing events and reported valuations.
Financials
Revenue and workforce over time
Available revenue and workforce history. Fields without reported data are omitted.
| Year | Revenue | Growth | Employees |
|---|---|---|---|
| 2026 | $867K | 0% | 3 |
| 2025 | $867K | 0% | 1 |
| 2024 | $867K | 0% | 1 |
| 2023 | $867K | 0% | 27 |
| 2022 | $867K | 0% | 27 |
| 2021 | $867K | 0% | 27 |
| 2020 | $867K | — | 30 |
Growth signals
StemoniX website traffic
Latest recorded traffic for StemoniX is 380 monthly website visits, down 35.6% over the last three months. StemoniX's team grew 200% over the past year.
Comparisons
StemoniX compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 NcardiaDrug discovery and development stem cell technology |
Leiden, Netherlands | Operational | 42 | $76M | $240M |
 MettleAILeveraging ML/AI to predict substance abuse relapse before it happens |
Toronto, Canada | Operational | |||
 Nostos GenomicsPartners with genetic labs to transform data into insights and deliver faster, clearer diagnoses for genetic diseases |
Berlin, Germany | Acquired | |||
 Lipigon PharmaceuticalsSpecialized in fat metabolism and develops new blood lipids |
Umeå kommun, Sweden | Operational | |||
 CardioDXCardiovascular genomic diagnostics |
Redwood City, United States | Operational | |||
 UltromicsAI-powered echocardiogram analysis for heart failure detection. |
Oxford, United Kingdom | Operational | |||
 Morphogen-IXEngineered protein therapeutics for pulmonary arterial hypertension |
Babraham, United Kingdom | Acquired | |||
 ABIONYXDeveloping of novel therapies for the treatment of cardiovascular and metabolic diseases |
Balma, France | Operational |
Capital deployed
StemoniX investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
StemoniX's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where StemoniX has talent and traffic
In the news
Latest news about StemoniX
Recent press, funding announcements, and product moves mentioning StemoniX — open to read from the original sources.
Market sentiment
What the market is saying about StemoniX
An AI-synthesized read of the highest-engagement posts about StemoniX on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See StemoniX’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.